Lilly to Showcase Data for Investigational Psoriasis Treatment at 24th European Academy of Dermatology and Venereology Congress

Oct 06, 2015, 09:00 ET from Eli Lilly and Company

INDIANAPOLIS, Oct. 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase results from the ixekizumab clinical development program during the 24th European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark, Oct. 7-11. Ixekizumab is the company's investigational medicine for the treatment of moderate-to-severe plaque psoriasis.

A total of 13 presentations, including a late-breaker oral presentation on Saturday, Oct. 10, will report results on the investigational medicine's efficacy, safety and patient-reported outcomes.

"For those with moderate-to-severe psoriasis, this chronic disease can affect many facets of their daily lives, including physical and emotional well-being, professional careers and personal relationships," said David Ricks, Lilly senior vice president, and president, Lilly Bio-Medicines. "The data to be presented provide further evidence about ixekizumab's potential, if approved, to help more people achieve clear skin and improve their quality of life."

Data to be presented include:
Oral Presentations:
Thursday, Oct. 8, 2015, 1:15-3:45 p.m. CEST: Session FC03, Location: B3M1-4

  • Safety and Tolerability of Ixekizumab: Analysis of Malignancies in Seven Clinical Studies of Moderate-to-Severe Plaque Psoriasis [Presenter: Strober, B.]

Saturday, Oct. 10, 2015, 8:00-11:15 a.m. CEST: Late-Breaker Session, Location: C1M4

  • Safety Profile of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Chronic Plaque Psoriasis Patients after at Least Three Years of Open-Label Treatment [Presenter: Lebwohl, M.]

Oral Poster Presentation:
Thursday, Oct. 8, 2015, 11:20-11:30 a.m. CEST: Session OP01, Location: Interactive e-Poster Area

  • Evaluation of Ixekizumab in Patients with Psoriasis and Psoriatic Arthritis: Results of a Pooled Analysis of Three Phase 3 Studies in Moderate-to-Severe Psoriasis [Presenter: Gottlieb, A.]

Poster Presentations:
Wednesday, Oct. 7 to Sunday, Oct. 11, 2015

  • Efficacy of Ixekizumab in Patients with Plaque Psoriasis – With and Without Previous Exposure to Biologic Therapies: Results at Weeks 12 and 60 from UNCOVER-1 [Lead author: Gerdes, S.]
  • Impact of Ixekizumab Treatment on Fingernail Psoriasis: Results from UNCOVER-1 [Lead author: Guenther, L.]
  • The Impact of Ixekizumab Treatment on Health-Related Quality of Life in Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1 [Lead author: Augustin, M.]
  • Impact of Ixekizumab on Psoriasis Itch Severity and Other Patient-Reported Outcomes: Results from UNCOVER-1 [Lead author: Kimball, A.]
  • Complete Resolution of Psoriasis is Associated with Greater Improvements in Itch and Health-Related Quality of Life: An Analysis from UNCOVER-1 [Lead author: Reich, K.]
  • Safety and Tolerability of Ixekizumab: Analysis of Neutropenia in Seven Clinical Studies of Moderate-to-Severe Plaque Psoriasis [Lead author: Strober, B.]
  • Safety and Tolerability of Ixekizumab: Analysis of Infections in Seven Clinical Studies of Moderate-to-Severe Plaque Psoriasis [Lead author: Papp, K.]
  • Impact of Ixekizumab Treatment on Sexual Function in Moderate-to-Severe Psoriasis Patients: 12-Week Results from UNCOVER-1 [Lead author: Guenther, L.]
  • Impact of Ixekizumab Treatment on Work Productivity in Patients with Moderate-to-Severe Plaque Psoriasis: Results from UNCOVER-1 [Lead author: Armstrong, A.]
  • Psychosocial Burden of Chronic Plaque Psoriasis Assessed in an Online Survey [Lead author: Cather, J.]

About ixekizumab
Ixekizumab is a monoclonal antibody with high affinity and specificity that binds to and neutralizes the pro-inflammatory cytokine interleukin-17A (IL-17A). In psoriasis, IL-17A plays a major role in driving excess keratinocyte (skin cell) proliferation and activation. Ixekizumab does not bind to cytokines IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. Ixekizumab is administered via subcutaneous injection (under the skin). Ixekizumab is also in clinical development for the treatment of psoriatic arthritis.

About the UNCOVER Studies
The UNCOVER studies are double-blind, multicenter, Phase 3 studies evaluating more than 3,800 patients with moderate-to-severe psoriasis in 18 countries. UNCOVER-1 compared the safety and efficacy of different dosing regimens of ixekizumab to placebo after 12 weeks and 60 weeks of treatment. The UNCOVER-2 and -3 studies assigned patients to receive either placebo, etanercept (50 mg twice a week) or ixekizumab (80 mg every two or four weeks) for 12 weeks, following a 160 mg starting dose.

About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.

P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about ixekizumab as a potential treatment for moderate-to-severe plaque psoriasis and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be similar to the results to date or that ixekizumab will receive regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.



Refer to: 

Tim Coulom; tim.coulom@lilly.com; 317-771-2241 (media)


Philip Johnson; johnson_philip_l@lilly.com; 317-655-6874 (investors)



 

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

SOURCE Eli Lilly and Company



RELATED LINKS

http://www.lilly.com